Pharmacotherapy of first-episode schizophrenia.
BACKGROUND
A growing interest in first-episode schizophrenia reflects the belief that this line of investigation will lead to further developments regarding schizophrenia's aetiology, course and outcome.


METHODS
Evidence from more recent clinical trials involving first-episode schizophrenia is integrated with neuroimaging data, specifically positron emission tomography, to provide direction regarding pharmacotherapy.


RESULTS
Individuals with a first episode of schizophrenia appear particularly responsive to pharmacotherapy, as well as quite sensitive to side-effects. At the same time, current clinical and receptor-binding data support the efficacy of low-dose neuroleptic treatment.


CONCLUSIONS
Early and effective treatment of schizophrenia has been associated with better long-term outcome. Low-dose neuroleptic therapy is an effective treatment strategy and the diminished risk of side-effects with this approach may further enhance compliance and outcome.
Department of Psychiatry, University of Toronto, Canada. gr@sig.clarke-inst.on.ca
G
G
Remington
S
S
Kapur
R B
RB
Zipursky
D014150:Antipsychotic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000517:prevention & control; D017050:Episode of Care; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D013997:Time Factors; D014055:Tomography, Emission-Computed; D016896:Treatment Outcome
D014150:Antipsychotic Agents